EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BIO-Europe 2015 BIO EBD Group
Share/Follow Us
Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BIO-Europe® 2015 Program Overview

www.ebdgroup.com/bioeurope/program
Sunday, November 1, 2015
19:00–21:30
Welcome Reception

Sunday, 19:00–21:30

HVB Forum

All BIO-Europe attendees are cordially invited to join us for a Welcome Reception.

You will be able to pick up your name badge at the welcome reception.

HVB Forum
Kardinal-Faulhaber-Straße 14
80333 Munich (map)

Since 1893 this magnificent building has been a financial center, from the Bavarian State Bank to HVB. It was completely renovated in the last 20 years and decorated with changing exhibitions of contemporary art to serve as an extraordinary event venue.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Monday, November 2, 2015
07:45
07:45
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
The evolving landscape of China's pharmaceutical industry

Monday, 09:00–10:30

China's pharmaceutical industry has grown at an unprecedented speed along with its booming economy. This has fueled much warranted excitement (and occasionally unfounded fantasies). Today, many opportunities in China are generating global impact in multiple dimensions: market sales, new innovations, talent pools, R&D outsourcing, public and private source of capitals and entrepreneurial initiatives. It was against this backdrop that major drug players ventured to this once mysterious nation, for pharmaceutical sales, R&D expansion and venture investment. Going forward China is poised to be the second largest pharmaceutical market. What are the drivers to sustain the continued growth? Will "Innovated in China" get any closer in replacing "Made in China"? What are the continued challenges and opportunities in capturing the growing opportunities in this huge land?

Moderator:
Darren Ji – Global Head and VP, Roche Partnering Asia and Emerging Markets, Roche

Panelists:
  • Jing Lou – President, Chairman, Co-Founder and CEO, 3SBio
  • Greg B. Scott – Founder and Chairman, ChinaBio® Group
  • Jimmy Wei – Venture Partner, KPCB China
  • Dan Zhang – Founder, Chairman and CEO, Fountain Medical, China
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Microbiome and human health: From understanding to intervention

Monday, 09:00–10:30

The gut microbiome makes up by far the largest number of cells in the human body. It is the most researched and best-known human symbiotic community. A healthy microbiome sets a person up for a healthy life; an imbalance (dysbiosis) can contribute to a range of diseases. This panel will discuss how this tipping-point from correlation (between diseases and dysbiosis) to causation (how microbiota-altering substances and habits contribute to disease) is understood and how the exponential growth of microbiome research can be translated into powerful new diagnostic and therapeutic products.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Big data: The digitized patient

Monday, 09:00–10:30

Now, more than ever before, we have access to information that can help transform the field of healthcare. Whether it's genomics, clinical data, or reimbursement records, the amount of data we have is overwhelming but we still don't have all the answers. What are the keys to unlocking the secrets within this data? How can we effectively mine all of this information to make impactful decisions in R&D? How can the data and the science be translated into new treatments? How can governments, academia, patients, and industry collaborate to use data in the most efficient way? This panel will address these questions and discuss how big data is being used to help change the future of medicine.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–12:30
Welcome and Opening Plenary Discussion
Welcome
Welcome and Opening Remarks

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Franz Pschierer – State Secretary in the Bavarian Ministry for Economic Affairs and Media, Energy and Technology
  • Horst Domdey – Managing Director, BioM
  • David Thomas – Director, Industry Research and Analysis, Biotechnology Industry Organization (BIO)
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opening Plenary Discussion
12:30–13:30
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development Track
To IPO or not to IPO: Why biotech companies should go public (or not), and where to do it

The decision to go public is riddled with both risk and reward. The number of companies that go through IPOs each year has long been an indication of wider industry health, as well as an appealing exit for investors. But is this still true today? What are the motivations and the pros and cons of going public for a biotech company? How can the process be managed to ensure a smooth transition both internally for the company as well as with investors? With the trend of European companies going public in the US, can and should incentives be developed to make European stock markets more appealing to home grown talent? Join a discussion with business leaders and representatives from stock exchanges and VCs experienced in navigating the divide between public and private.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alliance management

Alliances have never been more important for healthcare bottom lines, but getting the deal done is only the beginning of an even more important process: managing the expectations, personalities and progress of the partnership. Rather than sit back and let the collaboration unwind, these relationships can only blossom if challenges and working issues that arise are anticipated and structures are in place to ensure varying stresses are dealt with effectively. Alliance managers from leading pharma will tackle the importance of internal team alliance training, the role of organizational culture differences and adopting a proactive approach to partnership implementation.

Moderator:
Mark Archer – Global Head of Business Development, inVentiv Health

Panelists:
  • Patrick Benz – Senior Director Alliance Management, Johnson & Johnson Innovation
  • James O'Mara – Senior VP, Corporate Development, Ironwood Pharmaceuticals
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
VC involvement in external innovation strategies

External innovation provides new avenues to add products to pharma pipelines but also requires a significant investment of time and resources. Pharma, academia, biotech and venture capital each bring something unique to the collaborations that are essential to these models, but VCs occupy a unique position that allows them to bridge the separate worlds of business and research. Join these panelists as they discuss relationship design between strategic pharma partners, portfolio companies and the VCs whose contribution extends beyond financial involvement.

Moderator:
Hubert Birner – Managing Partner, TVM Life Science Management Inc.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alternative financing

It is said necessity is the mother of invention, and that applies to the funding of innovation as much as to any situation MacGyver might find himself in. Drug development lies at the crossroads of business and philanthropy and has access to funding from both worlds. The advent of personalized medicine has positioned patient groups and disease organizations in a unique position to contribute to the development of highly specialized drugs, financially and through involvement in aspects of the development process such as clinical trials. How do these new players contribute to the continuum of life science financing? What instruments are being used by these new sources and what innovations are later stage funders bringing to the table? For biotech companies, what considerations need to be taken with these and other sources of alternative finance?

Moderator:
Rûdiger Herrmann – Partner, Corporate, Life Sciences, Dechert LLP

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Spotlight Track
Global vaccine outlook

The worldwide vaccine market continues to grow as countries try to keep the threat of infectious diseases at bay. Pharma companies and government agencies from the United States and Europe will explore the need for cross-border collaborations to efficiently develop new vaccines, address the current international regulatory environment, and highlight opportunities for vaccine development, supply, pricing, procurement and dissemination to ensure access is available when needed.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bringing rare cancer therapies to market

Rarity (incidence of < 5/100,000) creates a number of hurdles in creating effective, affordable cancer treatments. Aside from the logistical difficulties of running clinical trials with extremely small populations, rarity also impacts the process of market authorization and securing reimbursement. Within the EU especially, navigating multiple national regulatory and reimbursement bodies can be overwhelming for clinicians, patients and companies. Join representatives from industry and public organizations as they examine potential solutions and the collaborations needed to get therapies to patients.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Advanced Therapies
Immuno-oncology: Combination therapies

As new advances in immuno-oncology evolve, we are observing unique combination therapies and the formation of atypical partnerships. This panel will examine collaborations among key players, how they are treating an array of cancers and how the industry is leveraging the advances in this sector.

Moderator:
Beatrice Gerard – VP, Advisory Services, Strategic Drug Development, Quintiles

Panelists:
  • Iain Dukes – Senior VP, Business Development and Licensing, MSD
  • Mohamed Ragab – VP, Head, Oncology Search and Evaluation, Business Development, Bristol-Myers Squibb
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Cell-based therapies for cancer

With all of the exciting developments in this field, this session will get past the hype and discuss the practical issues that need to be addressed in order for the promises of treatments to become reality. Hear company executives share their strategies to innovate, fund, partner, and commercialize the cell-based technologies that may truly disrupt healthcare.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Future business models for gene editing

As this technology evolves, executives face a unique set of challenges. Key business leaders will address a variety of business development issues such as: What is the future and the business model for these companies? If everything is given out in a non-exclusive manner, who owns the tech? What are the attainable goals? What is the capacity of these new technologies? What are the ethical issues this technology presents?

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma Presentations
13:30–18:30
One-to-one Meetings ►
18:00–18:45
Exhibit Hall Hospitality Reception
19:00–22:30
Evening Networking Reception with Buffet-style Dinner
Munich Residenz

Munich Residenz
Residenzstrasse
80333 Munich | (map)

The Munich Residenz served as the seat of government, residence and cultural center of the Bavarian dukes, electors and kings from 1508 to 1918. The largest city palace in Germany, it houses extensive room decorations, art and antiquities from the former royal collections.

18:45–19:15 Shuttle buses depart from the congress center to the evening event.
21:15–22:30 Shuttle buses depart from the evening event to all conference hotels.

Sponsored by:

Sanofi Bavaria
Tuesday, November 3, 2015
07:45
07:45
Exhibition opens and Continental Breakfast
09:00–11:00
Workshop
Innovative funding for SMEs in Europe

Tuesday, 09:00–10:30

With the shortage of early stage life sciences funding, the role of government in funding the next generation of cures is becoming increasingly important. In 2014, the European Union launched the SME instrument, a multibillion euro funding program dedicated to innovative Small and Medium-sized Enterprises (SMEs) in Europe as part of Horizon 2020. Under this program, a single SME can receive up to EUR 5 million for a project with 100% of the costs reimbursed by the EU. The session will provide an overview of this program and will also introduce other Horizon 2020 programs which are relevant for SMEs.

The session will have three presentations. One presentation will be made by a representative from the EU (European Commission – DG Research and Innovation – Health Directorate). Two European small businesses will then share their experience in leveraging government funding to move their technology towards clinical adoption and commercialization. A last presentation will be made by a representative from the EMA SME office and will introduce the Agency's support programs for SMEs.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter

Nanomedicine Award Ceremony

Tuesday, 10:30–11:00

The Nanomedicine Award promotes and rewards excellent new projects in nanomedicine. BIO-Europe is hosting the award ceremony of this award for the second time.

The Award is open to companies, academic and private researchers across the globe. The winners that will present their projects have developed innovative solutions based on nanomedicine that can ultimately change the way diseases are treated or diagnosed and that could provide new tools for physicians and benefits to patients.

Nominations for the Award will be accepted until September 15, 2015. More information can be found at nanomedicine-award.com.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:00–18:00
Company Presentations ►
08:00–18:30
One-to-one Meetings ►
12:00–13:00
Keynote Plenary Discussion
A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2015

Tuesday, 12:00–13:00

Moderators:
Anton Gueth – Managing Director, EVOLUTION Life Science Partners
Evonne Sepsis – Founder and Managing Director, ESC Advisors

Panelists:
  • Constantine Chinoporos – VP, Global Business Development and Licensing, Sanofi
  • George Golumbeski – Senior VP, Business Development, Celgene
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:00–14:00
Luncheon
13:00–14:00
Special lunch session
What you need to know about the life sciences landscape in Europe

Hosted by:

17:45–18:45
Exhibit Hall Hospitality Receptions
19:00–22:30
Evening Networking Reception with Buffet-style Dinner
Löwenbräukeller

Löwenbräukeller
Nymphenburgerstrasse 2
Am Stiglmaierplatz
80335 Munich | (map)

The Löwenbräukeller is a typical Bavarian location in Munich. It opened its doors in 1883, when the use of table linen and napkins as well as electric lighting in the whole building was a sensation. Today, the Löwenbräukeller is managed by Christian Schottenhamel, whose grandfather founded the first Oktoberfest beer tent on the Theresienwiese, a little shack with room for 50 people.

Sponsored by:

Bayer HealthCare

18:45–19:15 Shuttle buses depart from the congress center to the evening event.
21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

Wednesday, November 4, 2015
07:45
07:45
Exhibition opens and Continental Breakfast
9:00–13:00 Company Presentations ► 8:00–17:00
One-to-one Meetings ►
13:00–14:00
Luncheon
16:30
Closing Reception
Arrow Up


© 2009–2015 EBD GmbH